Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Prospect for more effective treatment of nerve pain

20.02.2017

Trigeminal neuralgia is characterized by sharp, lancinating pain in the teeth or facial area. The standard treatment for this chronic nerve pain can cause burdening side effects. A novel substance inhibits the pain effectively and is well tolerated, as documented by the initial results of an international study involving the Center of Dental Medicine at the University of Zurich.

The sharp pain shoots to the face or teeth and seriously torments patients. Known as trigeminal neuralgia, it is one of the worst chronic nerve pains. The bouts are triggered by touch, such as shaving, putting on make-up, showering, talking and tooth brushing, or even a gust of wind. The cause is usually an irritation of the trigeminal nerve, the cranial nerve responsible for the sensory innervation of the facial area, parts of the scalp, and the oral cavity.


Trigeminal neuralgia: A glimmer of hope for patients – thanks to a newly tested substance.

Picture: Center of Dental Medicine; UZH

However, there is now a glimmer of hope for patients: Thanks to a newly tested substance, the pain can be reduced to a tolerable level, as indicated by the promising results of an international phase II study involving the Center of Dental Medicine at the University of Zurich.


Less burdening side effects

Pain signals reach the brain via the activation of sodium channels located in the membranes of nerve cells. The sodium channel “1.7” is frequently expressed on pain-conducting nerves and higher pain intensity is linked to higher channel activity. Blocking this sodium channel – e.g. by a local anesthetic – inhibits the pain. In trigeminal neuralgia, the nerve damage is presumed to be at the base of the skull. However, this region is hard to reach by local injections and therefore requires drug treatment.


The novel substance BIIB074 which was tested in this phase II study inhibits the sodium channel 1.7 state-dependent, meaning: The more active this sodium channel gets, the stronger it is blocked by BIIB074. By contrast, currently available medications block the sodium channel 1.7 irrespective of the nerve activity, which commonly results in burdening side effects.

“Unlike conventional drugs, which often cause tiredness and concentration problems, BIIB074 was not only effective; but also very well tolerated,” explains Dominik Ettlin, a dental specialist from UZH. “We will now test the new substance in a lot more subjects during the next study phase, which will reveal whether the new hope for more effective pain relief is justified,” he concludes.


Literature:

Joanna Zakrzewska, Joanne Palmer, Valerie Morisset, Gerard Giblin, Mark Obermann, Dominik Ettlin, Giorgio Cruccu, Lars Bendtsen, Mark Estacion, Dominique Derjean, Stephen Waxman, Gary Layton, Kevin Gunn, and Simon Tate. Safety and efficacy of a Nav1.7 selective sodium channel blocker in trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. The Lancet Neurology, February 16, 2017. doi: 10.1016/S147-4422


Trigeminal neuralgia

Around 13 people in every 100,000 are diagnosed with trigeminal neuralgia every year – that’s around 1,100 throughout Switzerland. Trigeminal neuralgia affects more women than men, the majority of whom are pensioners. Around one percent of all multiple sclerosis patients develop trigeminal neuralgia.

Contact:

PD Dr. med., Dr. med. dent. Dominik Ettlin

Center of Dental Medicine

University of Zurich

Phone: +41 44 634 32 54

E-mail: dominik.ettlin@zzm.uzh.ch

Weitere Informationen:

http://www.media.uzh.ch/en/Press-Releases/2017/Effective-treatment-of-nerve-pain...

Nathalie Huber | Universität Zürich

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>